Key facts
- Basic Genomics’s last known valuation is $2.7M (Jan 2022).
- It has raised $1.7M; the latest was Early Stage VC ($1.2M) in Apr 2025.
- Notable investors include DRIVE ( KI Innovations Business Incubator), Navigare Ventures, Segulah Medical Acceleration.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Basic Genomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Basic Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Basic Genomics
Developer of advanced RNA-sequencing laboratory materials designed for transcript-level analysis purposes. The company's platform uses error patterns generated during reverse transcription to match short reads from the same RNA molecule and rebuild them into longer sequences, enabling researchers to access more detailed RNA information.
- Sector
- Healthcare
- HQ
- Stockholm, Sweden
- Founded
- 2021
- Employees
- 5
- Website
- basic-genomics.com/
- Ownership
- Privately Held (backing)
Basic Genomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Basic Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Basic Genomics in its N-PORT filings yet. We sweep new filings monthly.